Gene Expression Profiles in Multiple Sclerosis (MS)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Michelle Apperson, MD, University of California, Davis
ClinicalTrials.gov Identifier:
NCT00704834
First received: June 23, 2008
Last updated: November 29, 2012
Last verified: November 2012

June 23, 2008
November 29, 2012
March 2006
June 2015   (final data collection date for primary outcome measure)
  • Determine MS-specific peripheral blood gene expression patterns [ Time Frame: 3 years ] [ Designated as safety issue: No ]
  • Determine differences in peripheral blood gene expression patterns between subgroups of MS patients [ Time Frame: 3 years ] [ Designated as safety issue: No ]
  • Determine whether there are specific SNPs correlated with altered gene expression profiles in multiple sclerosis [ Time Frame: 3 years ] [ Designated as safety issue: No ]
  • Determine MS-specific peripheral blood inflammatory marker profiles [ Time Frame: 3 years ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00704834 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Gene Expression Profiles in Multiple Sclerosis (MS)
Gene Expression Profiles in Patients With Multiple Sclerosis

The purpose of this study is to test differences in RNA levels between Multiple Sclerosis (MS) patients and normal subjects. RNA provides a "message" from genes altered in diseases. We will also test DNA to determine if there are any small mutations called SNPs in any of the genes. The last tests are two separate tests for markers of inflammation called cytokines and eicosanoids. This research may lead to the discovery of biological markers for MS that are useful for diagnosis and treatment.

This is an investigator-initiated, pilot study of gene expression (RNA) in the blood of patients with multiple sclerosis (MS). The study will enroll patients from the UC Davis Multiple Sclerosis clinic. At a single study visit, we will confirm eligibility, obtain clinical information, and collect blood samples. We will then process these samples to obtain RNA for subsequent microarray analysis. DNA will also be used to examine single nucleotide polymorphisms (SNPs) on chips that allow us to examine 1 million of these SNPs. The SNPs may allow us to diagnose a disease like multiple sclerosis or to predict a treatment or cause. In addition, the DNA may be used to determine if there are any small mutations in any of the genes in the individuals who donate their blood. Additional studies will be done on blood plasma, testing for inflammatory molecules called eicosanoids and cytokines. The data from these tests will be superimposed on the microarray data to determine a molecular profile for each patient. We will then compare the data obtained between patient groups to determine gene alterations specific for each condition.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:

35cc of peripheral blood will be obtained from each subject via venipuncture.

Non-Probability Sample

Adult subjects aged 18 to 70 will be enrolled. There will be four study groups: patients with a clinically isolated syndrome (CIS), patients with untreated relapsing-remitting MS (RR-MS), patients with chronic, progressive MS (CPMS), and age- and gender-matched control subjects without MS. Patients of both sexes and all races will be recruited into the study without bias.

Multiple Sclerosis
Procedure: Blood Draw
35 cc of peripheral blood will be obtained by venipuncture from each subject.
  • 1
    Normal Controls
    Intervention: Procedure: Blood Draw
  • 2
    Patients with a clinically isolated syndrome (CIS)
    Intervention: Procedure: Blood Draw
  • 3
    Patients with relapsing, remitting Multiple Sclerosis (RRMS) who are not on treatment
    Intervention: Procedure: Blood Draw
  • 4
    Patients with Chronic Progressive Multiple Sclerosis who are not on treatment
    Intervention: Procedure: Blood Draw
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
120
June 2015
June 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • males and females
  • any race
  • Between the ages of 18 and 70 years
  • Diagnosed with a clinically isolated syndrome or the diagnosis of multiple sclerosis using the widely established Macdonald criteria. A 'clinically isolated syndrome' refers to an isolated attack of optic neuritis, transverse myelitis, or brain demyelination. Relapsing-remitting MS is characterized by acute relapses that are followed by some degree of recovery without worsening of disability between relapses. Chronic progressive MS is defined as sustained progression of physical disability, occurring separately from relapses, in patients with MS.
  • Control subjects will be male or female, between the ages 18 to 70 years, of any race, with no symptoms of MS.

Exclusion Criteria:

  • Children are excluded from the study because MS is generally a disease of young adult onset and is rare in children.
  • Evidence of infection or communicable disease, cancer or other known systemic disease, anti-coagulation, known bleeding disorder, illicit drug abuse, or change in medications in the last 30 days (including treatment with steroids).
  • Patients receiving any other immune modulating medications (steroids, cyclophosphamide, mitoxantrone, methotrexate, mycophenolate mofetil, azathioprine, IVIG or rituximab) in the prior thirty days will be excluded from the study
Both
18 Years to 70 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00704834
200614150
No
Michelle Apperson, MD, University of California, Davis
Michelle Apperson, MD
Not Provided
Principal Investigator: Michelle Apperson, MD, PhD University of California, Davis
University of California, Davis
November 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP